Press Releases

Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19

Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch of its patent-pending flagship product, Epi+Gen CHD. The Epi+Gen CHD test sensitively assesses the risk for the onset of new coronary heart disease, an ability that is key to providing cost-effective health care for adults. Despite the importance of preventative health in cardiovascular disease, for the past 30

EmitBio Inc., a life science company using the precise delivery of light to stimulate, protect and heal the body, today announced clinical results from its investigational treatment for adults with mild-to-moderate COVID-19. In a placebo-controlled, randomized double-blind clinical trial, 4 days of treatment with the EmitBio device* achieved a 99.9% reduction in average viral load of SARS-CoV-2, the virus that causes COVID-19, and accelerated time to symptom resolution in patients b

The Asia Pacific Consortium on Osteoporosis (APCO) has today (Thursday, January 28, 2021) launched the first pan-Asia Pacific clinical practice standards for the screening, diagnosis, and management of osteoporosis, targeting a broad range of high-risk groups. Published in Osteoporosis International today, "The APCO Framework" comprises 16 minimum clinical standards set to serve as a benchmark for the provision of optimal osteoporosis care in the region. Develope

Eli Lilly and Company, Vir Biotechnology, Inc. and GlaxoSmithKline plc announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein. This unique collaboration marks the first ti

Thermo Fisher Scientific has developed a new medium for the development and expansion of human T lymphocytes (T-cells) for cell therapy developers using allogeneic workflows. The Gibco CTS OpTmizer Pro Serum Free Media (SFM) is a first-of-its-kind media-solution that targets the metabolism of healthy donor cells, making it ideally suited for use in the production of allogeneic, off-the-shelf cell therapies. In contrast to autologous cell therapies, which are produced using a patient

BridgeBio Pharma, Inc.announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own. The transaction was overwhelmingly approved by BridgeBio and Eidos stockholders. The merger reunites the teams at BridgeBio and Eidos and allows BridgeBio to deploy its full clinical and commercial infrastructure to support the development and global commercial

The recently hosted CPhI & P-MEC China 2020 – organized by Informa Markets and CCCMHPIE and co-organized by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd. – attracted a remarkable 46,157 visits of professional pharma visitors, including 5,105 international attendees taking part online. The hybrid event has helped stimulate renewed growth a

Quercis Pharma AG , a private clinical-stage biopharmaceutical company that leverages its new antithrombotic platform, announced that it has entered into an exclusive, global licensing agreement for two patents with the Beth Israel Deaconess Medical Center (BIDMC), an affiliate of Harvard Medical School, focusing on modulation, risk reduction of thrombotic pathologies and thrombotic events in cancer patients. These patents relate to the main pathways of thrombotic inhibitors, including P-sele

Aurinia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN). LUPKYNIS is the first FDA-approved oral therapy for LN. LN causes irreversible kidney damage and significantly increases the risk of kidney failure, cardiac events, and death. It is one of the most serious and common complications of the autoimmu